Published in Diabetes Metab Syndr Obes on September 02, 2013
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 8.47
Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes (1974) 5.55
High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care (1998) 3.94
Atherogenesis: a postprandial phenomenon. Circulation (1979) 3.74
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet (2009) 3.67
The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 2.73
Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ (2005) 2.24
Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia (2001) 2.12
Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia (1984) 1.99
The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev (2000) 1.30
Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J Pharmacol (2001) 1.29
Insulin responses in equivocal and definite diabetes, with special reference to subjects who had mild glucose intolerance but later developed definite diabetes. Diabetes (1977) 1.25
Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. Br J Nutr (2007) 1.25
The postprandial state and risk of cardiovascular disease. Diabet Med (1998) 1.23
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab (2011) 1.17
The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J (2011) 1.13
Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol (2010) 1.08
The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes (2004) 1.02
Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther (1994) 1.00
Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids Health Dis (2009) 0.97
Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men. Metabolism (2006) 0.96
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther (2009) 0.96
The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol (2001) 0.94
Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell. Eur J Pharmacol (1994) 0.94
Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia (2005) 0.93
Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab (2011) 0.93
Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients--an analysis of the DiaRegis registry. Cardiovasc Diabetol (2011) 0.91
Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract (2002) 0.89
Postprandial state and atherosclerosis. Curr Opin Lipidol (1995) 0.89
Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide. Cardiovasc Diabetol (2012) 0.86
Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother (2013) 0.84
Sulfonylureas and the risk of myocardial infarction. Metabolism (2006) 0.82
Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. Curr Vasc Pharmacol (2008) 0.81
Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother (2012) 0.80
Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. Endocrine (2006) 0.80
Mitiglinide, a novel oral hypoglycemic agent, preserves the cardioprotective effect of ischemic preconditioning in isolated perfused rat hearts. Int Heart J (2007) 0.79
Effects of mitiglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts. Eur J Pharmacol (2006) 0.79
Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother (2008) 0.77
Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res (2009) 0.77
Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. J Int Med Res (2010) 0.77
Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother (2010) 0.77
Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocr J (2010) 0.77
Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus. J Diabetes Investig (2011) 0.76
Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. Ann Pharmacother (2010) 0.76
Nateglinide with glibenclamide examination using the respiratory quotient (RQ). J Med Invest (2006) 0.76
The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. Diabetes (2005) 3.00
Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology (2003) 2.53
Phosphofructokinase deficiency; past, present and future. Curr Mol Med (2002) 1.52
A decreased number of c- kit-expressing cells in a patient with afferent loop syndrome. J Gastroenterol (2003) 1.41
Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J (2013) 1.22
Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest (2002) 1.19
Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care (2002) 1.18
Deficiency of KIT-positive cells in the colon of patients with diabetes mellitus. J Gastroenterol Hepatol (2002) 1.06
Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus. Diabetes Ther (2013) 1.03
Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J (2009) 1.03
Liver regeneration in heparin-binding EGF-like growth factor transgenic mice after partial hepatectomy. Gastroenterology (2003) 1.01
Hepatocyte nuclear factor-1alpha modulates pancreatic beta-cell growth by regulating the expression of insulin-like growth factor-1 in INS-1 cells. Diabetes (2002) 0.98
The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. J Cell Physiol (2008) 0.95
New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Clin Exp Nephrol (2012) 0.95
Evaluation of a minimally invasive system for measuring glucose area under the curve during oral glucose tolerance tests: usefulness of sweat monitoring for precise measurement. J Diabetes Sci Technol (2013) 0.90
The -1535 promoter variant of the visfatin gene is associated with serum triglyceride and HDL-cholesterol levels in Japanese subjects. Endocr J (2008) 0.90
Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus. Thromb Res (2002) 0.90
Neogenesis and proliferation of beta-cells induced by human betacellulin gene transduction via retrograde pancreatic duct injection of an adenovirus vector. Biochem Biophys Res Commun (2006) 0.89
Metabolic consequence of long-term exposure of pancreatic beta cells to free fatty acid with special reference to glucose insensitivity. Biochim Biophys Acta (2002) 0.89
Expression of HNF-4alpha (MODY1), HNF-1beta (MODY5), and HNF-1alpha (MODY3) proteins in the developing mouse pancreas. Gene Expr Patterns (2007) 0.87
Up-regulation of the expression of activins in the pancreatic duct by reduction of the beta-cell mass. Endocrinology (2002) 0.86
Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocr J (2012) 0.86
Medium-term effects of insulin degludec on patients with type 1 diabetes mellitus. Drugs R D (2014) 0.85
Thyroid hormone receptor interacting protein 3 (trip3) is a novel coactivator of hepatocyte nuclear factor-4alpha. Diabetes (2002) 0.84
Incretin responses to oral glucose load in Japanese non-obese healthy subjects. Diabetes Ther (2011) 0.83
Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide. Diabetes Res Clin Pract (2004) 0.80
Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. Endocr J (2011) 0.80
Role of macrophages in the development of pancreatic islet injury in spontaneously diabetic torii rats. Exp Anim (2009) 0.80
Overexpression of pituitary adenylate cyclase-activating polypeptide in islets inhibits hyperinsulinemia and islet hyperplasia in agouti yellow mice. J Pharmacol Exp Ther (2004) 0.79
NF-kappaB activation in non-parenchymal liver cells after partial hepatectomy in rats: possible involvement in expression of heparin-binding epidermal growth factor-like growth factor. J Hepatol (2002) 0.79
Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism (2010) 0.78
Porphyrias in Japan: compilation of all cases reported through 2002. Int J Hematol (2004) 0.78
[Insulin therapy in diabetic patient with hypertension]. Nihon Rinsho (2003) 0.77
[Incretin-based therapy in patients with type 1 diabetes mellitus]. Nihon Rinsho (2011) 0.75
Anaplastic thyroid carcinoma accompanied by uncontrollable eosinophilia. Intern Med (2015) 0.75
[Glucagonoma]. Nihon Rinsho (2006) 0.75
Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist. Intern Med (2016) 0.75
[Significance of the regulation of hyperglucagonemia in type 2 diabetes mellitus]. Nihon Rinsho (2015) 0.75
Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes. Endocr J (2014) 0.75
[A fulminant type 1 diabetes with multiple organ failure at the onset of diabetes]. Nihon Naika Gakkai Zasshi (2008) 0.75
[Therapeutic indications of incretin-related derivatives and other oral hypoglycemic agents]. Nihon Rinsho (2012) 0.75
[Current concept of insulin therapy intensification, and the role of human regular insulin and rapid-acting insulin analogs in insulin treatment]. Nihon Rinsho (2015) 0.75
Sequence analysis of mouse muscle-type phosphofructokinase gene introns 10 and 11 with special reference to the exon skipping. Res Commun Mol Pathol Pharmacol (2004) 0.75
[Insulin treatment in elder patients with diabetes]. Nihon Rinsho (2006) 0.75
[A new method of communication and education for diabetics by glucose monitoring via Internet]. Nihon Rinsho (2002) 0.75
[Homeostasis model assessment as a clinical index of insulin resistance]. Nihon Rinsho (2006) 0.75
[The socio-medical issues of elderly diabetic patients]. Nihon Ronen Igakkai Zasshi (2006) 0.75
[Incretin related agents for treatment of diabetes mellitus]. Nihon Naika Gakkai Zasshi (2009) 0.75
[Strategy of insulin therapy in type 1 diabetes]. Nihon Rinsho (2012) 0.75
[Case report: A case of deep coma with early diagnosed myxedema]. Nihon Naika Gakkai Zasshi (2012) 0.75
[Programs for continuing medical education: a session; 7. Recent trends in treatment of diabetes mellitus]. Nihon Naika Gakkai Zasshi (2014) 0.75
Partial HPRT Deficiency with a Novel Mutation of the HPRT Gene in Combination with Four Previously Reported Variants Associated with Hyperuricemia. Intern Med (2015) 0.75
[GLP-1 derivatives, for the prevention and treatment of type 2 diabetes mellitus]. Nihon Shokakibyo Gakkai Zasshi (2005) 0.75
[DPP-4 inhibitor (incretin enhancer)]. Nihon Rinsho (2012) 0.75